Valproic acid increases the SMN2 protein level: A well-known drug as a potential therapy for spinal muscular atrophy

Human Molecular Genetics

Volumn 12, Issue 19, 2003, Pages 2481-2489

  Brichta, L ^a,b   Hofmann, Y ^a   Hahnen, E ^c   Siebzehnrubi, F A ^c   Raschke, H ^a   Blumcke, I ^c   Eyupoglu, I Y ^c   Wirth, B ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MESSENGER RNA; PROTEIN SMN2; SURVIVAL MOTOR NEURON 2 PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ALTERNATIVE RNA SPLICING; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROBLAST CULTURE; GENE NUMBER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOTONEURON; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA SPLICING; SPINAL MUSCULAR ATROPHY; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EXONS; FIBROBLASTS; GABA AGENTS; GENE DELETION; GENE EXPRESSION REGULATION; GENE THERAPY; HIPPOCAMPUS; HUMANS; MUSCULAR ATROPHY, SPINAL; NERVE TISSUE PROTEINS; ORGAN CULTURE TECHNIQUES; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC; VALPROIC ACID;

ANIMALIA;

EID: 0141506887     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/ddg256     Document Type: Article

References (39)

1. Pearn, J. (1978) Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J. Med. Genet., 15, 409-413.
2. Feldkotter, M., Schwarzer, V., Wirth, R., Wienker, T.F. and Wirth, B. (2002) Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet., 70, 358-368.
3. Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruand, C., Millasseau, P., Zeviani, M. et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell, 80, 155-165.
4. Wirth, B. (2000) An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum. Mutat., 15, 228-237.
5. Scheffer, H., Cobben, J.M., Matthijs, G. and Wirth, B. (2001) Best practice guidelines for molecular analysis in spinal muscular atrophy. Eur. J. Hum. Genet., 9, 484-491.
6. Munsat, T.L. and Davies, K.E. (1992) International SMA consortium meeting (26-28 June 1992, Bonn, Germany). Neuromuscul. Disord., 2, 423-428.
7. Liu, Q., Fischer, U., Wang, F. and Dreyfuss, G. (1997) The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell, 90, 1013-1021.
8. Pellizzoni, L., Kataoka, N., Charroux, B. and Dreyfuss, G. (1998) A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell, 95, 615-624.
9. Rossoll, W., Kroning, A.K., Ohndorf, U.M., Steegborn, C., Jablonka, S. and Sendtner, M. (2002) Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons? Hum. Mol. Genet., 11, 93-105.
10. Schrank, B., Gotz, R., Gunnersen, J.M., Ure, J.M., Toyka, K.V, Smith, A.G. and Sendtner, M. (1997) Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl Acad. Sci. USA, 94, 9920-9925.
11. Lorson, C.L., Hahnen, E., Androphy, E.J. and Wirth, B. (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA, 96, 6307-6311.
12. Cartegni, L. and Krainer, A.R. (2002) Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet., 30, 377-384.
13. Kashima, T. and Manley, J.L. (2003) A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet., 34, 460-463.
14. Lorson, C.L., Strasswimmer, J., Yao, J.M., Baleja, J.D., Halmen, E., Wirth, B., Le, T., Burghes, A.H. and Androphy, E.J. (1998) SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet., 19, 63-66.
15. Burghes, A.H. (1997) When is a deletion not a deletion? When it is converted. Am. J. Hum. Genet., 61, 9-15.
16. Helmken, C., Hofmann, C., Schoenen, F., Oprea, G., Raschke, H., Rudnik-Schöneborn, S., Zerres, K. and Wirth, B. (2003) Evidence for a modifying pathway in SMA discordant families; Reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum. Genet., in press.
17. Hofmann, Y., Lorson, C.L., Stamm, S., Androphy, E.J. and Wirth, B. (2000) Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc. Natl Acad. Sci. USA, 97, 9618-9623.
18. Hofmann, Y. and Wirth, B. (2002) hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1. Hum. Mol. Genet., 11, 2037-2049.
19. Young, P.J., DiDonato, C.J., Hu, D., Kothary, R., Androphy, E.J. and Lorson, C.L. (2002) SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2beta1. Hum. Mol. Genet., 11, 577-587.
20. Chang, J.G., Hsieh-Li, H.M., Jong, Y.J., Wang, N.M., Tsai, C.H. and Li, H. (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl Acad. Sci. USA, 98, 9808-9813.
21. Andreassi, C., Jarecki, J., Zhou, J., Coovert, D.D., Monani, U.R., Chen, X., Whitney, M., Pollok, B., Zhang, M., Androphy, E. et al. (2001) Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum. Mol. Genet., 10, 2841-2849.
22. Zhang, M.L., Lorson, C.L., Androphy, E.J. and Zhou, J. (2001) An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene. Ther, 8, 1532-1538.
23. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, J.R, Lo Coco, F., Nervi, C., Pelicci, P.G. et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 20, 6969-6978.
24. Labiner, D.M. (2002) DP-VPA D-Pharm. Curr. Opin. Investig. Drugs, 3, 921-923.
25. Blaheta, R.A. and Cinatl, J., Jr (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med. Res. Rev., 22, 492-511.
26. Wlodarczyk, B.C., Craig, J.C., Bennett, G.D., Calvin, J.A. and Finnell, R.H. (1996) Valproic acid-induced changes in gene expression during neurulation in a mouse model. Teratology, 54, 284-297.
27. Arinze, I.J. and Kawai, Y. (2003) Sp family of transcription factors is involved in valproic acid-induced expression of Galpha i2. J. Biol. Chem., 278, 17785-17791.
28. Echaniz-Laguna, A., Miniou, P., Bartholdi, D. and Melki, J. (1999) The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements. Am. J. Hum. Genet., 64, 1365-1370.
29. Stoppini, L., Buchs, P.A. and Muller, D. (1991) A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods, 37, 173-182.
30. Savaskan, N.E., Eyupoglu, I.Y., Brauer, A.U., Plaschke, M., Ninnemann, O., Nitsch, R. and Skutella, T. (2000) Entorhinal cortex lesion studied with the novel dye fluoro-jade. Brain Res., 864, 44-51.
31. Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P.A. et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA, 100, 2041-2046.
32. Wieser, H.G. (1991) Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res., 9, 154-159.
33. Pazin, M.J. and Kadonaga, J.T. (1997) What's up and down with histone deacetylation and transcription? Cell, 89, 325-328.
34. Johannessen, C.U. (2000) Mechanisms of action of valproate: a cornmentatory Neurochem. Int., 37, 103-110.
35. Lindhout, D. and Omtzigt, J.G. (1992) Pregnancy and the risk of teratogenicity. Epilepsia, 33 (suppl. 4), S41-48.
36. Jumaa, H. and Nielsen, P.J. (1997) The splicing factor SRp20 modifies splicing of its own mRNA and ASF/SF2 antagonizes this regulation. EMBO J., 16, 5077-5085.
37. Nayler, O., Cap, C. and Stamm, S. (1998) Human transformer-2-beta gene (SFRS10): complete nucleotide sequence, chromosomal localization, and generation of a tissue-specific isoform. Genomics, 53, 191-202.
38. Misteli, T., Caceres, J.F. and Spector, D.L. (1997) The dynamics of a pre-mRNA splicing factor in living cells. Nature, 387, 523-527.
39. Cartegni, L. and Krainer, A.R. (2003) Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat. Struct. Biol., 10, 120-125.